Oragenics (OGEN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

OGEN Oragenics

Watchlist

1.2700
+0.2500+24.51%

Close Aug 27 16:00 ET

7.09MMarket Cap-173P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Oragenics Shares Are Trading Higher After the Company Announced the Filing Completion for Its ONP-002 Drug in Anticipation of Its Phase IIa Clinical Trail in Concussed Patients
BenzingaAug 21 08:48 ET
Express News | Oragenics - Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase Iia Clinical Trial in Concussed Patients
ReutersAug 21 08:36 ET
Express News | EXCLUSIVE: Oragenics Tells Benzinga 'No Pharmaceutical Treatment Is Available for Concussion; Drug, ONP-002, Could Be First of Its Kind to Treat Concussion'
BenzingaAug 21 08:30 ET
Express News | EXCLUSIVE: Oragenics Tells Benzinga Co. Completes Spray Dry Drug Manufacturing And Intranasal Device Filling In Anticipation Of Phase IIa Clinical Trial In Concussed Patients
BenzingaAug 21 08:30 ET
Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients
OragenicsAug 21 00:00 ET
Oragenics Files to Sell 2.4M Shares of Common Stock
Seeking AlphaAug 16 16:58 ET

Comments

Jaguar8

Aug 16 15:52

NEWS

$Oragenics (OGEN.US)$
Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
Oragenics (NYSE American: OGEN) has provided an update on its drug ONP-002, intended to treat concussion, and its non-compliance with NYSE American continued listing standards. Key developments include:
1. Demonstrated stability of ONP-002 across a wide temperature range.
2. Preparation for Phase 2 clinical trials, expected to start i...

Jaguar8

Aug 14 12:06

NEWS

$Oragenics (OGEN.US)$
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
Oragenics Inc. (NYSE American: OGEN) has announced that its lead candidate for treating concussion, ONP-002, demonstrates stability across a wide temperature range (-20°C to 104°C). This eliminates the need for cold storage, making it suitable for field use in sports and military operations. Key points:
1. ONP-002 is a new chemical entitydesigned for in...

103622690 DK

Aug 12 15:34

$Oragenics (OGEN.US)$ Oragenics Inc: Onp-002 Showed No Cancer-Causing DNA Damage

103622690 DK

Aug 12 08:24

$Oragenics (OGEN.US)$ As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032

103622690 DK

Aug 12 08:24

$Oragenics (OGEN.US)$ EXCLUSIVE: Oragenics Tells Benzinga 'The Potential Addressable Market Opportunity for ONP-002 Includes an Estimated 69 Million Concussions Globally'

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

OGEN Oragenics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target